Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous NSCLC 1Neoplasms, Unknown Primary 1Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Esophageal Squamous Cell Carcinoma 1Advanced/Metastatic Solid Malignancies 1

Interventions

Paclitaxel 6Carboplatin 6Gemcitabine 3pembrolizumab 2Irinotecan 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1erythromycin propionate-N-acetylcysteinate 1entrectinib 1cobimetinib 1belinostat 1atezolizumab 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1Vemurafenib 1Surveys and Questionnaires 1Oxaliplatin 1HhAntag691 1Everolimus 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Unknown Primary × sintilimab × Clear all
NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Completed
10 enrolled 9 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡